Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of mocetinostat when given together
with vinorelbine to see how well it works in treating children, adolescents, and young adults
with rhabdomyosarcoma that has spread to nearby tissues or lymph nodes and cannot be removed
by surgery (locally advanced unresectable) or has spread to other places in the body
(metastatic), and does not respond to treatment (refractory) or has come back (relapsed).
Mocetinostat may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving mocetinostat and vinorelbine may work better in treating
children, adolescents, and young adults with rhabdomyosarcoma compared to vinorelbine alone.